Cargando…

Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer

The number of older patients with cancer is increasing as a result of the ageing of Western societies. Immune checkpoint inhibitors have improved cancer treatment and are associated with lower rates of treatment-related toxicity compared with chemotherapy in the general population. Nonetheless, immu...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Holstein, Yara, Kapiteijn, Ellen, Bastiaannet, Esther, van den Bos, Frederiek, Portielje, Johanneke, de Glas, Nienke A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764930/ https://www.ncbi.nlm.nih.gov/pubmed/31317421 http://dx.doi.org/10.1007/s40266-019-00697-2

Ejemplares similares

Time Trends in Treatment Strategies and Survival of Older versus Younger Patients with Synchronous Metastasised Melanoma—A Population-Based Study in the Netherlands Cancer Registry
por: van der Ziel, Daisy, et al.
Publicado: (2022)

Improved survival of older patients with advanced breast cancer due to an increase in systemic treatments: a population-based study
por: de Glas, Nienke, et al.
Publicado: (2019)

Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors †
por: de Glas, Nienke A., et al.
Publicado: (2021)

Early stage breast cancer treatment and outcome of older patients treated in an oncogeriatric care and a standard care setting: an international comparison
por: de Boer, Anna Z., et al.
Publicado: (2020)

Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review
por: Baltussen, Joosje C., et al.
Publicado: (2021)

Chemotherapy-Related Toxic Effects and Quality of Life and Physical Functioning in Older Patients
por: Baltussen, Joosje C., et al.
Publicado: (2023)

Design and rationale of a routine clinical care pathway and prospective cohort study in older patients needing intensive treatment
por: van Holstein, Yara, et al.
Publicado: (2021)

Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer
por: Lemij, Annelieke A., et al.
Publicado: (2022)

Prediction of Other-Cause Mortality in Older Patients with Breast Cancer Using Comorbidity
por: de Boer, Anna Z., et al.
Publicado: (2021)

Effectiveness of radiotherapy after breast-conserving surgery in older patients with T1-2N0 breast cancer
por: de Boer, Anna Z., et al.
Publicado: (2019)

A Prediction Model for Severe Complications after Elective Colorectal Cancer Surgery in Patients of 70 Years and Older
por: Souwer, Esteban T. D., et al.
Publicado: (2021)

Effect of implementation of the mass breast cancer screening programme in older women in the Netherlands: population based study
por: de Glas, Nienke A, et al.
Publicado: (2014)

Frailty and checkpoint inhibitor toxicity in older patients with melanoma
por: Bruijnen, Cheryl P., et al.
Publicado: (2022)

Physical Function and Physical Activity in Older Breast Cancer Survivors: 5-Year Follow-Up from the Climb Every Mountain Study
por: Lemij, Annelieke A, et al.
Publicado: (2023)

Rheumatic Immuno-related Adverse Events following Immunotherapy with Checkpoint Inhibitors: Adverse Drug Reaction, or Other?
por: Manzo, Ciro
Publicado: (2021)

The impact of geriatric characteristics and comorbidities on distant metastases and other cause mortality in older women with non-metastatic breast cancer treated with primary endocrine therapy
por: Waaijer, M. E.C., et al.
Publicado: (2023)

A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer
por: Abedian Kalkhoran, Hanieh, et al.
Publicado: (2023)

Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy
por: Jing, Ying, et al.
Publicado: (2020)

The Effect of A Geriatric Assessment on Treatment Decisions for Patients with Lung Cancer
por: Schulkes, Karlijn J. G., et al.
Publicado: (2017)

Ocular adverse events with immune checkpoint inhibitors
por: Fang, Tony, et al.
Publicado: (2019)

Mucocutaneous adverse events to immune checkpoint inhibitors
por: Muhaj, Fiorinda, et al.
Publicado: (2023)

Unexpected Adverse Events of Immune Checkpoint Inhibitors
por: Shalata, Walid, et al.
Publicado: (2023)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
por: Brahmer, Julie R, et al.
Publicado: (2021)

The Prognostic Value of a Geriatric Risk Score for Older Patients with Colorectal Cancer
por: Souwer, E. T. D., et al.
Publicado: (2018)

Differences in treatment and survival of older patients with operable breast cancer between the United Kingdom and the Netherlands – A comparison of two national prospective longitudinal multi-centre cohort studies
por: van der Plas-Krijgsman, Willeke G., et al.
Publicado: (2022)

Validity of the online PREDICT tool in older patients with breast cancer: a population-based study
por: de Glas, N A, et al.
Publicado: (2016)

Primary Endocrine Therapy in Older Women with Breast Cancer
por: Pepping, R. M. C., et al.
Publicado: (2017)

Immune-Related Adverse Events in the Older Adult with Cancer Receiving Immune Checkpoint Inhibitor Therapy
por: Biniakewitz, Matthew D., et al.
Publicado: (2020)

Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults
por: Schonfeld, Sara J., et al.
Publicado: (2022)

Testing the effects on information use by older versus younger women of modality and narration style in a hospital report card
por: Yılmaz, Nida Gizem, et al.
Publicado: (2021)

Imaging of Adverse Events Related to Checkpoint Inhibitor Therapy
por: Vani, Vanina, et al.
Publicado: (2020)

Cardiac Adverse Events Related to Immune Checkpoint Inhibitors
por: Gujral, Dorothy M., et al.
Publicado: (2020)

The Role of Pharmacists in Managing Adverse Events Related to Immune Checkpoint Inhibitor Therapy
por: Medina, Patrick, et al.
Publicado: (2019)

Gastrointestinal adverse events of immunotherapy
por: Cappello, Giovanni, et al.
Publicado: (2021)

Modeling Diagnostic Strategies to Manage Toxic Adverse Events following Cancer Immunotherapy
por: van Delft, Frederik, et al.
Publicado: (2021)

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
por: Kostine, Marie, et al.
Publicado: (2021)

Effect of omission of surgery on survival in patients aged 80 years and older with early‐stage hormone receptor‐positive breast cancer
por: de Boer, A. Z., et al.
Publicado: (2020)

Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors
por: Wang, Zheng-Hang, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
por: Herrmann, Sandra M., et al.
Publicado: (2020)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
por: Si, Xiaoyan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h94fhvj5niujnjfjlqsrpte7ce